Identification of a signature of histone modifiers in kidney renal clear cell carcinoma

Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aging (Albany, NY.) NY.), 2024-06, Vol.16 (12), p.10489-10511
Hauptverfasser: Huang, Yongming, Yang, Zhongsheng, Tang, Ying, Chen, Hua, Liu, Tairong, Peng, Guanghua, Huang, Xin, He, Xiaolong, Mei, Ming, Du, Chuance
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10511
container_issue 12
container_start_page 10489
container_title Aging (Albany, NY.)
container_volume 16
creator Huang, Yongming
Yang, Zhongsheng
Tang, Ying
Chen, Hua
Liu, Tairong
Peng, Guanghua
Huang, Xin
He, Xiaolong
Mei, Ming
Du, Chuance
description Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.
doi_str_mv 10.18632/aging.205944
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3070794640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</originalsourceid><addsrcrecordid>eNpVkc1vGyEQxVGVqvnqsdeKYy7rwvKxcKqqKG0tRcolVY5ovAwOyS64sI7k_77rOIlSLgyan97w5hHyhbMFN1q032Ad03rRMmWl_EBOuJWqkcrYo3f1MTmt9YExrZTUn8ixMPNRXJ2Qu6XHNMUQe5hiTjQHCrTGdYJpW3D_vI91ygnpmP2MYak0JvoYfcIdLZhgoP2AUGiPw1xC6WPKI5yTjwGGip9f7jPy5-fV7eXv5vrm1_Lyx3XTc2NlgyoIa2ww3nRMW679KnBleqVbCMi8BtXZFaD0AoTGlUDWBQUYtDehFVacke8H3c12NaLvZzMFBrcpcYSycxmi-7-T4r1b5yfHeSu0YGZWuHhRKPnvFuvkxlj3ZiBh3lYnWMc6K7VkM9oc0L7kWguGtzmcuec03HMa7pDGzH99_7k3-nX94h9Zx4in</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070794640</pqid></control><display><type>article</type><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</creator><creatorcontrib>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</creatorcontrib><description>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</description><identifier>ISSN: 1945-4589</identifier><identifier>EISSN: 1945-4589</identifier><identifier>DOI: 10.18632/aging.205944</identifier><identifier>PMID: 38888515</identifier><language>eng</language><publisher>United States: Impact Journals</publisher><subject>Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - metabolism ; Epigenesis, Genetic ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Histones - genetics ; Histones - metabolism ; Humans ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - genetics ; Prognosis ; Research Paper ; Transcriptome</subject><ispartof>Aging (Albany, NY.), 2024-06, Vol.16 (12), p.10489-10511</ispartof><rights>Copyright: © 2024 Huang et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236308/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236308/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38888515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yongming</creatorcontrib><creatorcontrib>Yang, Zhongsheng</creatorcontrib><creatorcontrib>Tang, Ying</creatorcontrib><creatorcontrib>Chen, Hua</creatorcontrib><creatorcontrib>Liu, Tairong</creatorcontrib><creatorcontrib>Peng, Guanghua</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>He, Xiaolong</creatorcontrib><creatorcontrib>Mei, Ming</creatorcontrib><creatorcontrib>Du, Chuance</creatorcontrib><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><title>Aging (Albany, NY.)</title><addtitle>Aging (Albany NY)</addtitle><description>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - metabolism</subject><subject>Epigenesis, Genetic</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Histones - genetics</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - genetics</subject><subject>Prognosis</subject><subject>Research Paper</subject><subject>Transcriptome</subject><issn>1945-4589</issn><issn>1945-4589</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1vGyEQxVGVqvnqsdeKYy7rwvKxcKqqKG0tRcolVY5ovAwOyS64sI7k_77rOIlSLgyan97w5hHyhbMFN1q032Ad03rRMmWl_EBOuJWqkcrYo3f1MTmt9YExrZTUn8ixMPNRXJ2Qu6XHNMUQe5hiTjQHCrTGdYJpW3D_vI91ygnpmP2MYak0JvoYfcIdLZhgoP2AUGiPw1xC6WPKI5yTjwGGip9f7jPy5-fV7eXv5vrm1_Lyx3XTc2NlgyoIa2ww3nRMW679KnBleqVbCMi8BtXZFaD0AoTGlUDWBQUYtDehFVacke8H3c12NaLvZzMFBrcpcYSycxmi-7-T4r1b5yfHeSu0YGZWuHhRKPnvFuvkxlj3ZiBh3lYnWMc6K7VkM9oc0L7kWguGtzmcuec03HMa7pDGzH99_7k3-nX94h9Zx4in</recordid><startdate>20240617</startdate><enddate>20240617</enddate><creator>Huang, Yongming</creator><creator>Yang, Zhongsheng</creator><creator>Tang, Ying</creator><creator>Chen, Hua</creator><creator>Liu, Tairong</creator><creator>Peng, Guanghua</creator><creator>Huang, Xin</creator><creator>He, Xiaolong</creator><creator>Mei, Ming</creator><creator>Du, Chuance</creator><general>Impact Journals</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240617</creationdate><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><author>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - metabolism</topic><topic>Epigenesis, Genetic</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Histones - genetics</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - genetics</topic><topic>Prognosis</topic><topic>Research Paper</topic><topic>Transcriptome</topic><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yongming</creatorcontrib><creatorcontrib>Yang, Zhongsheng</creatorcontrib><creatorcontrib>Tang, Ying</creatorcontrib><creatorcontrib>Chen, Hua</creatorcontrib><creatorcontrib>Liu, Tairong</creatorcontrib><creatorcontrib>Peng, Guanghua</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>He, Xiaolong</creatorcontrib><creatorcontrib>Mei, Ming</creatorcontrib><creatorcontrib>Du, Chuance</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Aging (Albany, NY.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yongming</au><au>Yang, Zhongsheng</au><au>Tang, Ying</au><au>Chen, Hua</au><au>Liu, Tairong</au><au>Peng, Guanghua</au><au>Huang, Xin</au><au>He, Xiaolong</au><au>Mei, Ming</au><au>Du, Chuance</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</atitle><jtitle>Aging (Albany, NY.)</jtitle><addtitle>Aging (Albany NY)</addtitle><date>2024-06-17</date><risdate>2024</risdate><volume>16</volume><issue>12</issue><spage>10489</spage><epage>10511</epage><pages>10489-10511</pages><issn>1945-4589</issn><eissn>1945-4589</eissn><abstract>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</abstract><cop>United States</cop><pub>Impact Journals</pub><pmid>38888515</pmid><doi>10.18632/aging.205944</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1945-4589
ispartof Aging (Albany, NY.), 2024-06, Vol.16 (12), p.10489-10511
issn 1945-4589
1945-4589
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236308
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - metabolism
Epigenesis, Genetic
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Histones - genetics
Histones - metabolism
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Prognosis
Research Paper
Transcriptome
title Identification of a signature of histone modifiers in kidney renal clear cell carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T04%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20a%20signature%20of%20histone%20modifiers%20in%20kidney%20renal%20clear%20cell%20carcinoma&rft.jtitle=Aging%20(Albany,%20NY.)&rft.au=Huang,%20Yongming&rft.date=2024-06-17&rft.volume=16&rft.issue=12&rft.spage=10489&rft.epage=10511&rft.pages=10489-10511&rft.issn=1945-4589&rft.eissn=1945-4589&rft_id=info:doi/10.18632/aging.205944&rft_dat=%3Cproquest_pubme%3E3070794640%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070794640&rft_id=info:pmid/38888515&rfr_iscdi=true